Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methotrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 4/20 | 1.00 |
| ▸ | FPGS | Q05932 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TLR4 | O00206 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TYMS | P04818 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | FOLR2 | P14207 | 1/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | GART | P22102 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methotrexate SCHEMBL3712 | 1.00 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL20548444 | 1.00 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL8216266 | 1.00 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL16013534 | 1.00 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL171251 | 1.00 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL29349432 | 1.00 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3711 | 1.00 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL23111684 | 0.99 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL22690831 | 0.99 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL9281141 | 0.99 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100490850-C | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN NINGBO YINGNUO PHARMACE (CN) | 2009-05-27 | — | — | CN | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| WO-2005079419-A2 | METHODS OF TREATING IMMUNOPATHOLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-01 | — | — | WO | claimed |
| CN-1655814-A | Selective antibody of tumor necrosis factor related apoptosis inducing ligand receptor and use thereof | UAB RESEARCH FOUNDATION (US) | 2005-08-17 | — | — | CN | claimed |
| CN-1630516-A | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents | UAB RESEARCH FOUNDATION (US) | 2005-06-22 | — | — | CN | claimed |
| US-11883405-B2 | Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | AMPLIO PHARMA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| CN-116848139-A | BCMA/TACI antigen binding molecules | 蜂鸟生物科技私人有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116710564-A | Oncolytic viruses enhance T cell response to effective TIL therapy | H·李·莫菲特癌症中心和研究所公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4228658-A1 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF | George Mason Research Foundation, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022262859-A1 | ANTI-HUMAN MSLN HUMANIZED ANTIBODY AND USE THEREOF | 江苏先声药业有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-20220396796-A1 | RNA FOR CANCER THERAPY | CUREVAC AG (DE) | 2022-12-15 | — | — | US | disclosed |
| EP-0914157-B1 | ANTI-TNF ANTIBODIES / TNF RECEPTOR AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASE | KENNEDY INST OF RHEUMATOLOGY (GB) | 2005-10-05 | — | — | EP | disclosed |
| US-20050209665-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20020136723-A1 | Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease | THE KENNEDY INSTITUTE OF RHEUMATOLOGY | 2002-09-26 | — | — | US | disclosed |
| EP-1170017-A1 | Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition | THE KENNEDY INSTITUTE OF RHEUMATOLOGY (GB) | 2002-01-09 | — | — | EP | disclosed |
| US-5051260-A | Hydroxypolyurethanes as moisturizers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-09-24 | — | — | US | disclosed |
| US-5045317-A | Using polyetherurethane copolymers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-09-03 | — | — | US | disclosed |
| US-4971800-A | DRUG DELIVERY THROUGH SKIN, PENETRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883405-B2 | Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | MTX1, MTX2, SSB | DHFR 10/4885FPGS 44/4885KDM4E 4465/4885 |
| US-20220396796-A1 | RNA FOR CANCER THERAPY | NSUN3, RNASE1, TRDMT1 | DHFR 2770/4885FPGS 3200/4885KDM4E 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.